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A pharmacophore model of F508del-CFTR was used to virtually screen ~6 million
commercial compounds, resulting in two diverse sets of 250 compounds each:
1. one resulting from pharmacophoric ﬁngerprint of known correctors;
2. another ﬁtting into putative binding sites for F508del-CFTR identiﬁed by the model.
The 1st set was previously screened by two parallel medium-throughput methodologies:
1. quantitative Western blot to assess rescue of F508del-CFTR processing in CFBE
cells; and
2. wt- and F508del-NBD1 folding and stability assays, using differential scanning
ﬂuorimetry.
This screen identiﬁed 4 primary “hit” compounds causing extensive rescue and/or
stabilization of NBD1.
The effect of these compounds on F508del-CFTR trafﬁcking was here assessed
by a microscopy-based assay performed in A549 cells expressing a double tagged
ﬂag/mCherry CFTR construct under an inducible (Tet-ON) promoter. The ratio of
total CFTR at the membrane (assessed by an anti-Flag antibody without cell perme-
abilization) over the total CFTR expressed (given by the mCherry ﬂuorescence) was
determined per cell for these 4 hits. Values were (±SEM): DMSO − 0.415±0.008;
C9 − 0.445±0.004; C5 − 0.373±0.004; E12 − 0.497±0.005; B9 − 0.387±0.004. The
same assay is being applied to CFBE cells with the same construct at 37ºC and a
secondary library of 46 compounds derived from these 4 lead primary “hits” is also
under assessment.
Work supported by PTDC/SAU-GMG/122299/2010 grant (POCTI/FCT/PIDDAC, Por-
tugal) and PEst-OE/BIA/UI4046/2011 centre grant. Authors thank CFF-USA for
correctors (B. Bridges, Chicago, USA).
Reference(s)
[1] Almac¸a J, Dahime`ne S et al (2011) Methods Mol Biol 742, 249−64.
